Market Cap 49.15M
Revenue (ttm) 43.77M
Net Income (ttm) -35.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -80.05%
Debt to Equity Ratio 0.00
Volume 60,900
Avg Vol 40,425
Day's Range N/A - N/A
Shares Out 5.78M
Stochastic %K 54%
Beta -0.15
Analysts Sell
Price Target $20.00

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 524 2466
Website: xiliotx.com
Address:
828 Winter Street, Suite 300, Waltham, United States
LabPsycho
LabPsycho Apr. 8 at 5:55 PM
$XLO Yep. There does not appear to be many sellers left. Three phases of XLO Seller Sucking include: 1. Drifting down for months before the reverse split 2. The Dilution to raise $$$ near lows, then the R/S 3. The ups and downs (mostly downs) of the war And then the reverse split Now it seems Buyers just nibbling trying not to tip their hand or move the price but it is inching up, next step is move in strides (Risk is 75% to the upside / 25% to the downside in my estimation) could be in 2-3 weeks IMO.
0 · Reply
biohuntress
biohuntress Apr. 8 at 3:48 PM
$XLO hopefully clearing out the last of the sellers between 8-9
0 · Reply
LabPsycho
LabPsycho Apr. 7 at 2:46 PM
$XLO Let me preface this post with stating I am not a buyout kind of believer for most biotechs. IMO, if it weren't for the seemingly imminent global apocalypse, one might be tempted to be like a trading bot and slowly accumulate 100-200 shares at a time slightly above the bid (if possible?). If GILD does come calling, one would want this closer to 18 so the 75 - 150% premium would get this above $30 At least $30-40 seems reasonable - $XLO has $44M market cap with at least $130 million (if not ~$175 million!!) cash and partnerships with Abbvie, Roche and Gilead. If XLO produces any positive clinical data, its also a 3X from here with such a low float. But, global uncertainty and another round of 50% 'transient' inflation putting a damper on things. Good luck
0 · Reply
CagedMoney
CagedMoney Apr. 7 at 2:20 PM
$XLO 🔥
0 · Reply
809trader
809trader Apr. 7 at 12:35 PM
$XLO next is XLO Gilead also has a partnership with tubullis before the buyout and they also raised nice cash before the buyout. LFG 😛🥳😛 https://x.com/biostocks/status/2041491519098470442?s=12&t=wHopsM6AxwgEZIfi0ZU3Hg
2 · Reply
809trader
809trader Apr. 7 at 12:09 PM
$XLO imagine when they drop the vilastobart partnership. Jesus baby lord.
0 · Reply
LabPsycho
LabPsycho Apr. 6 at 1:48 PM
$XLO Watching the trading, it looks to me like most of the sellers are gone. Volume very low while not trying to tip the hand (big price swings) = quiet accumulation. I stand by my prediction several weeks ago...this will likely be over $10 this month, followed by a transient a drop to $9, then a run when all the phony "we called this run" types (dbr_island, diamond-dog, etc) that want you to join their family show up getting this to $14. Good luck
1 · Reply
809trader
809trader Apr. 2 at 3:30 PM
$XLO looks like insiders are under nda’s. No buyers at all even though they are all under water. Director bought the top so far $9.25….data in 2 weeks will probably release them from nda
1 · Reply
bailingniao88
bailingniao88 Apr. 1 at 3:41 PM
$XLO director bought 5000 shares one day ago...a very good news showing confidence in their progress
1 · Reply
LabPsycho
LabPsycho Apr. 1 at 2:59 PM
$XLO The comparisons below are a bit of a stretch so feel free to bash. Could masked immunotherapy could supercharge some already encouraging clinical results (from other companies)? XLO is Early-stage. Later stage Novabridge Bioscience 👇 Their CLDN18.2 bispecific has shown encouraging clinical activity in GI cancers—especially in combo settings. tolerability can limit full potential XLO = potentially same (or better) efficacy, less collateral damage Same story with IL-12 👇 Imunon has shown impressive Phase 2 results in ovarian cancer using IL-12. Clear anti-tumor activity but historically limited by systemic toxicity $XLO’s Efarindodekin alfa (masked IL-12) If masking works, potentially: • Higher effective dosing • Better tumor-localized immune activation • Fewer systemic side effects CLDN18.2 seems validated IL-12 also validated Rebuttals?
1 · Reply
Latest News on XLO
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Mar 12, 2026, 8:30 AM EDT - 27 days ago

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split


Xilio Therapeutics Announces Pricing of Underwritten Offering

Feb 11, 2026, 9:34 PM EST - 2 months ago

Xilio Therapeutics Announces Pricing of Underwritten Offering


Xilio Therapeutics Announces Proposed Public Offering

Jun 2, 2025, 6:11 AM EDT - 11 months ago

Xilio Therapeutics Announces Proposed Public Offering


LabPsycho
LabPsycho Apr. 8 at 5:55 PM
$XLO Yep. There does not appear to be many sellers left. Three phases of XLO Seller Sucking include: 1. Drifting down for months before the reverse split 2. The Dilution to raise $$$ near lows, then the R/S 3. The ups and downs (mostly downs) of the war And then the reverse split Now it seems Buyers just nibbling trying not to tip their hand or move the price but it is inching up, next step is move in strides (Risk is 75% to the upside / 25% to the downside in my estimation) could be in 2-3 weeks IMO.
0 · Reply
biohuntress
biohuntress Apr. 8 at 3:48 PM
$XLO hopefully clearing out the last of the sellers between 8-9
0 · Reply
LabPsycho
LabPsycho Apr. 7 at 2:46 PM
$XLO Let me preface this post with stating I am not a buyout kind of believer for most biotechs. IMO, if it weren't for the seemingly imminent global apocalypse, one might be tempted to be like a trading bot and slowly accumulate 100-200 shares at a time slightly above the bid (if possible?). If GILD does come calling, one would want this closer to 18 so the 75 - 150% premium would get this above $30 At least $30-40 seems reasonable - $XLO has $44M market cap with at least $130 million (if not ~$175 million!!) cash and partnerships with Abbvie, Roche and Gilead. If XLO produces any positive clinical data, its also a 3X from here with such a low float. But, global uncertainty and another round of 50% 'transient' inflation putting a damper on things. Good luck
0 · Reply
CagedMoney
CagedMoney Apr. 7 at 2:20 PM
$XLO 🔥
0 · Reply
809trader
809trader Apr. 7 at 12:35 PM
$XLO next is XLO Gilead also has a partnership with tubullis before the buyout and they also raised nice cash before the buyout. LFG 😛🥳😛 https://x.com/biostocks/status/2041491519098470442?s=12&t=wHopsM6AxwgEZIfi0ZU3Hg
2 · Reply
809trader
809trader Apr. 7 at 12:09 PM
$XLO imagine when they drop the vilastobart partnership. Jesus baby lord.
0 · Reply
LabPsycho
LabPsycho Apr. 6 at 1:48 PM
$XLO Watching the trading, it looks to me like most of the sellers are gone. Volume very low while not trying to tip the hand (big price swings) = quiet accumulation. I stand by my prediction several weeks ago...this will likely be over $10 this month, followed by a transient a drop to $9, then a run when all the phony "we called this run" types (dbr_island, diamond-dog, etc) that want you to join their family show up getting this to $14. Good luck
1 · Reply
809trader
809trader Apr. 2 at 3:30 PM
$XLO looks like insiders are under nda’s. No buyers at all even though they are all under water. Director bought the top so far $9.25….data in 2 weeks will probably release them from nda
1 · Reply
bailingniao88
bailingniao88 Apr. 1 at 3:41 PM
$XLO director bought 5000 shares one day ago...a very good news showing confidence in their progress
1 · Reply
LabPsycho
LabPsycho Apr. 1 at 2:59 PM
$XLO The comparisons below are a bit of a stretch so feel free to bash. Could masked immunotherapy could supercharge some already encouraging clinical results (from other companies)? XLO is Early-stage. Later stage Novabridge Bioscience 👇 Their CLDN18.2 bispecific has shown encouraging clinical activity in GI cancers—especially in combo settings. tolerability can limit full potential XLO = potentially same (or better) efficacy, less collateral damage Same story with IL-12 👇 Imunon has shown impressive Phase 2 results in ovarian cancer using IL-12. Clear anti-tumor activity but historically limited by systemic toxicity $XLO’s Efarindodekin alfa (masked IL-12) If masking works, potentially: • Higher effective dosing • Better tumor-localized immune activation • Fewer systemic side effects CLDN18.2 seems validated IL-12 also validated Rebuttals?
1 · Reply
AskSmacker
AskSmacker Mar. 31 at 5:35 PM
$XLO Looks like this closed about four weeks ago based on my notes—good progress. I believe they mentioned at Leerink Partners Global Healthcare Conference that the IND filing is on track, which is encouraging. I’d expect an update sometime between June and August.
0 · Reply
LabPsycho
LabPsycho Mar. 31 at 2:59 PM
$XLO @AskSmacker - Good post and timely info. I am usually a bit tentative when insiders buy thinking it could be a head fake, but I thinks its encouraging that this XLO insider paid close to the recent high after the split. XLO has been drifting down for a long time, then did a dilution, then a reverse split...its looking to me like most of the sellers are gone. Quiet accumulation likely but I see a burst to near $20 by year end. $XLO market cap of only ~$42 million with at least $130 million in cash, if not $170 million after their recent, pre-dilution raise, plus the potential for more $$$ from GILEAD in a year makes XLO stand out a bit IMO.
0 · Reply
AskSmacker
AskSmacker Mar. 31 at 1:15 PM
$XLO Director James Samuel Shannon has signaled confidence in Xilio Therapeutics by purchasing 5,000 shares of the company’s stock in a recent transaction, with the buy valued at $43,950. https://www.sec.gov/Archives/edgar/data/1485417/000119312526131745/xslF345X06/ownership.xml
0 · Reply
LabPsycho
LabPsycho Mar. 30 at 3:14 PM
$XLO @Jtlo And smart money will be adding starting at $9.90. Good luck
0 · Reply
Jtlo
Jtlo Mar. 26 at 4:21 PM
$XLO they will start chasing when this is at 12
1 · Reply
PerryvillePlays
PerryvillePlays Mar. 26 at 3:20 PM
$XLO Recent RS, 3M float. Has crappy pre-funded warrants. There is an upcoming catalyst Apr 17-22 (poster presentation at the Amer Assoc for Cancer Research). Look on Finviz and check out all the tutes and funds in here. I grabbed 2 weeks ago, I'm fine with low and slow until it gets volume.
1 · Reply
kubota2323
kubota2323 Mar. 26 at 2:43 PM
$XLO Giddy Up.
0 · Reply
LabPsycho
LabPsycho Mar. 26 at 2:22 PM
$XLO Frankly, I was expecting XLO to drop after the R/S (as many RS stocks do) to ~ $6.40 after the R/S, but perhaps in a way it did a couple days before the 14 for 1 R/S hitting ~40 cents. Anyhow, here is what I expect for XLO (my bots analyzing A.I.trading bots – ha – they always tip their hand a bit when the Grift is getting close). I think XLO could drift up to $10.20…sit there a bit, then an arbitrary pantsing of ~ $1, then sitting there as 68, 202 and other weird numbers of shares get traded, while keeping the price in a +/- 40 cent range. Could be weeks or longer while shares are accumulated by both bots and low float (temporarily reticent) pumpers, trying not to move the price too much. Then watch for the volume increase, that could be a signal for a run. All based on NO new releases. Wild speculation of course – share your ideas!
1 · Reply
bailingniao88
bailingniao88 Mar. 26 at 3:48 AM
$XLO Labpsycho: I have been following your predictions last year they are really incredible! Lets hope your track record is good for XLO too
2 · Reply
Anonymouspapertrader
Anonymouspapertrader Mar. 25 at 5:36 PM
$XLO Look like a move to Friday PM. Should come back on the 30M to test the 50 sma. All time frames still look good not even the 1minute has testes the 200 yet.
0 · Reply
LabPsycho
LabPsycho Mar. 25 at 1:35 PM
$XLO Currently Bid: $8.06, Ask: $8.74 Now that is a gap! = IMO, likely going higher.
0 · Reply
kubota2323
kubota2323 Mar. 25 at 2:02 AM
$XLO https://www.reuters.com/business/healthcare-pharmaceuticals/merck-nears-6-billion-all-cash-deal-buy-terns-pharma-ft-reports-2026-03-25/ so long to TERN
0 · Reply